Erenumab + Ethynil Estradiol/Norgestimate Oral Contraceptive
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Headache, Migraine
Conditions
Headache, Migraine
Trial Timeline
Feb 12, 2016 → Sep 9, 2016
NCT ID
NCT02792517About Erenumab + Ethynil Estradiol/Norgestimate Oral Contraceptive
Erenumab + Ethynil Estradiol/Norgestimate Oral Contraceptive is a phase 1 stage product being developed by Amgen for Headache, Migraine. The current trial status is completed. This product is registered under clinical trial identifier NCT02792517. Target conditions include Headache, Migraine.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02792517 | Phase 1 | Completed |
Competing Products
20 competing products in Headache, Migraine
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + LY2300559 | Eli Lilly | Phase 2 | 52 |
| Ketorolac + Prochlorperazine + Diphenhydramine | Assertio Holdings | Phase 2 | 44 |
| Aricept (donepezil hydrochloride) | Eisai | Phase 2 | 52 |
| Galcanezumab 300 mg + Placebo | Eli Lilly | Phase 3 | 77 |
| Galcanezumab | Eli Lilly | Phase 3 | 77 |
| Galcanezumab-Gnlm | Eli Lilly | Approved | 85 |
| LY2590443 + Placebo injection + Sumatriptan + Placebo capsule | Eli Lilly | Phase 2 | 52 |
| LY2951742 + Placebo | Eli Lilly | Phase 2 | 52 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Galcanezumab + Placebo | Eli Lilly | Phase 2 | 52 |
| Soy Isoflavones | Johnson & Johnson | Pre-clinical | 23 |
| topiramate | Johnson & Johnson | Phase 3 | 77 |
| Ubrogepant 50 MG [Ubrelvy] + Ubrogepant 100 MG [Ubrelvy] | AbbVie | Approved | 85 |
| Placebo + Zolmitriptan + Zolmitriptan + Zolmitriptan | AstraZeneca | Approved | 85 |
| candesartan cilexetil + placebo | AstraZeneca | Phase 2 | 52 |
| Rizatriptan + Placebo | Merck | Pre-clinical | 23 |
| Propranolol or nadolol + Placebo control + Optimal Acute Therapy | Merck | Approved | 85 |
| AMG 334 | Novartis | Phase 2 | 52 |
| SOM230 + Placebo | Novartis | Phase 2 | 52 |
| Erenumab | Amgen | Phase 2 | 51 |